Skip to main content
Skip to navigation
Print subscriptions
Sign in
Search jobs
Search
International edition
International edition
UK edition
US edition
Australia edition
Europe edition
The Guardian - Back to home
The Guardian
News
Opinion
Sport
Culture
Lifestyle
Show
More
Show More
News
View all News
World news
UK news
Climate crisis
Ukraine
Environment
Science
Global development
Football
Tech
Business
Obituaries
Opinion
View all Opinion
The Guardian view
Columnists
Cartoons
Opinion videos
Letters
Sport
View all Sport
Olympics 2024
Football
Cricket
Rugby union
Tennis
Cycling
F1
Golf
US sports
Culture
View all Culture
Books
Music
TV & radio
Art & design
Film
Games
Classical
Stage
Lifestyle
View all Lifestyle
Fashion
Food
Recipes
Love & sex
Health & fitness
Home & garden
Women
Men
Family
Travel
Money
Search input
google-search
Search
Support us
Print subscriptions
International edition
UK edition
US edition
Australia edition
Europe edition
Search jobs
Holidays
Digital Archive
Guardian Licensing
About Us
The Guardian app
Video
Podcasts
Pictures
Newsletters
Today's paper
Inside the Guardian
The Observer
Guardian Weekly
Crosswords
Wordiply
Corrections
Search jobs
Holidays
Digital Archive
Guardian Licensing
About Us
Shire
8 May 2018
Nils Pratley on finance
Challenger banks discover they won't get far on their own
Nils Pratley
Virgin Money’s deal with CYBG makes commercial logic but it won’t reshape the banking sector
Business live
UK house prices fall; Takeover drama at Shire and Virgin Money - as it happened
All the day’s economic and financial news, including the latest on two takeover deals
Adderall maker Shire agrees £46bn takeover by Takeda
Japanese drugmaker increases offer to secure biggest deal since 2000 in pharmaceutical sector
April 2018
Shire board recommends £46bn takeover by Japanese drugmaker Takeda
Deal for the FTSE100 company and maker of ADHD drug will be one of the biggest ever
Nils Pratley on finance
Shire saga smells of overadventurous engineering
Nils Pratley
It is not obvious that Takeda or Allergan can make the takeover numbers work
Shire rebuffs Takeda takeover bid as Allergan drops out
Shire shares rise after Allergan said it was considering making an offer for maker of ADHD medicine Adderall
March 2018
Nils Pratley on finance
Reckitt Benckiser needs to wean itself off a dud pay model
Nils Pratley
Shire's shares surge as Japan's Takeda considers bid
February 2017
Observer business agenda
Brexit: the price of post-truth pounds in our pockets
Simon Goodley
Fifty years after Harold Wilson’s speech, people are still talking a load of nonsense about sterling
November 2016
Market Forces blog
FTSE 100 edges higher with Shire benefitting from a problem at rival Roche
Shire shares fall after reporting drop in sales of haemophilia drugs
August 2016
Market Forces blog
Pharmaceutical shares fall on Clinton comments on excessive drug prices
Market Forces blog
Old Mutual falls after results while Shire slips on deal talk
June 2016
Top FTSE 100 bosses landed pay rises of nearly £100m in 2015
Market Forces blog
Shire climbs on prospects for Baxalta merger
May 2016
Three more companies face shareholder wrath over executive pay
Investors revolt over pay at AGMs of Ladbrokes, Reckitt Benckiser and Carillion, following rebellions at BP, Shire and others
April 2016
Shire and Weir bosses feel sting of investor ire as pay revolts widen
Drug maker and engineer not alone on day shareholders use AGMs to protest en masse against boardroom bonuses and pay
Business live
Executive pay: Shareholder revolts at Weir and Shire- as it happened
Shareholder spring in full swing as investors oppose pay deals
Market Forces blog
EasyJet slips after update but Shire climbs as deal concerns fade
Shire recovers as analysts say US tax rules should not affect Baxalta plan
March 2016
Market Forces blog
FTSE 100 moves higher but Halfords leads retailers lower on outlook fears
Analysts at UBS point to cautious consumer environment and Amazon worries
About 273 results for Shire
1
2
3
4
...
Explore more on these topics
Pharmaceuticals industry
Stock markets
Executive pay and bonuses
Economics
Reckitt Benckiser